Cerrahpaşa Medical Faculty Hospital HIV-1/-2 Serological Test Data: 2019-2022 Retrospective Evaluation

Year 2022, Volume: 12 Issue: 3, 215 - 218, 31.12.2022

Harika Öykü Dinç Elif Keskin Banu Tufan Koçak Bekir Kocazeybek

https://doi.org/10.26650/experimed.1191760

Abstract

Objective: The aim of this study was to retrospectively discuss the human immunodeficiency virus (HIV) scanning and verification test results and demographics of patients who were admitted to the Istanbul University Cerrahpaşa Medical Faculty’s Medical Microbiology Laboratory Center Serology/ELISA division with suspected HIV infection or pre-operative serologic screening. In addition, the study aimed to compare HIV seroprevalence with data from the center’s previous period.

Materials and Methods: HIV-1/-2 antibody +P24 antigen (HIV-1/-2 Ab/Ag) was studied routinely using the chemiluminescent microparticle immunoassay (CMIA) method with the same method also being used as the second repeat test. The sera verifications of patients who showed repeated reactivity after the HIV Ab/Ag test were studied using the line immunoassay (LIA) method.

Results: The study retrospectively studied 156,542 cases between 2019-2022, of which 237 (0.17%) showed repeated anti-HIV-1/-2 reactivity. From the repeated reactivity serum samples, LIA testing was performed to confirm the remaining 181 serum samples after excluding the previously confirmed samples, with 175 (96.6%) coming back positive. All these samples showed sgp120 and gp41 band positivity, thus confirming HIV1 positivity.

Conclusion: These retrospective data from one center regarding HIV seroprevalence for the 2019-2022 period are in line with other national studies. However, due to the COVID-19 pandemic, HIV prevalence during this period may have been higher than detected. HIV prevalence in Istanbul, being a cosmopolitan city that receives immigrants, should be monitored in the future.

Keywords

HIV-1/2, CMIA, LIA, Serological Diagnostic

References

• 1. WHO. Estimated number of people (all ages) living with HIV. (cited 2022 Nov 29). Available from: https://www.who.int/data/gho/ data/indicators/indicator-details/GHO/estimated-number-of-people--living-with-hiv. google scholar
• 2. WHO (2021). Research & development for HIV/AIDS. (cited 2022 Nov 29). Available from: https://www.who.int/observatories/ global-observatory-on-health-research-and-development/ analyses-and-syntheses/hiv-aids/priority-setting-for-research-on-hiv-aids google scholar
• 3. CDC. Moving towards the UNAIDS 90-90-90 targets. (cited 2022 Nov 29). Available from: https://www.cdc.gov/globalhealth/ stories/2019/moving-towards-unaids.html google scholar
• 4. HIV and AIDS Activities: HIV Testing, US Food and Drug Administration. (cited 2022 Nov 29). Available from: https://www. fda.gov/forpatients/ illness/hivaids/default.htm google scholar
• 5. WHO and HIV/AIDS. Geneva: World Health Organization. (cited 2022 Nov 29). Available from: http://www.who.int/hiv/en google scholar
• 6. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Türkiye HIV/ AIDS Kontrol Programı (2019-2024) Ankara, 2019. (cited 2022 Nov 29). Available from: https://hsgm.saglik.gov.tr/depo/birimler/ Bulasici-hastaliklar-db/hastaliklar/HIV-ADS/Tani-Tedavi_Rehberi/ HIV_AIDS_Kontrol_Programi.pdf google scholar
• 7. UNAIDS. Available from: https://aidsinfo.unaids.org/. google scholar
• 8. Toluk Ö, Ercan İ, Akalın H. Seçilmiş bazı Avrupa ülkelerindeki HIV enfeksiyonu ve tüberkülozun insidanslarının istatistiksel proses kontrol yöntemi ile izlenmesi. J Med Sci 2021; 41(1): 36-45. [CrossRef] google scholar
• 9. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. HIV-AIDS istatistik. (cited 2022 Nov 29). Available from: https://hsgm.saglik. gov.tr/tr/bulasici-hastaliklar/hiv-aids/hiv-aids-liste/hiv-aids-istatislik. google scholar
• 10. Dinç HÖ, Özbey D, Sirekbasan S, Gareayaghi N, Kocazeybek B. İstanbul Üniversitesi-Cerrahpaşa Cerrahpaşa Tıp Fakültesi Hastanesi 2015-2018 dönemi HIV tarama ve doğrulama verilerinin seroepidemiyolojik değerlendirilmesi. ANKEM 2019; 33(3): 89-94 google scholar
• 11. Yüksel P, Ziver T, İzmirli S, Aslan M, Sarıbaş S, Güngördü Z, et al. Anti-HIV-pozitif hastalarda doğrulama testi sonuçları: Beş yıllık verilerin irdelenmesi. Klimik 2010; 23(2): 51-4. [CrossRef] google scholar
• 12. Öner P, Aytaç Ö. Ferda Şenol F, Aşçı Toraman Z. Özgüler M. Elâzığ ili dokuz yıllık HIV/AIDS sonuçlarının analizi. Turk Mikrobiyol Cemiy Derg 2020; 50(2): 100-7. google scholar
• 13. Gökengin D, Oprea C, Uysal S, Begovac J. The growing HIV epidemic in Central Europe: a neglected issue? J Virus Erad 2016; 2(3): 156-61. [CrossRef] google scholar
• 14. Erdinç FŞ, Dokuzoğuz B, Ünal S, Yıldırmak T, Kömür S, Fincancı M et al. Changing trends in the epidemiology of Turkey. In: 30th IUSTI Europe Conference (15-17 September 2016, Budapest, Hungary) Abstract Book. UK: International Union Against Sexually Transmitted Infections, 2016: 115-6. google scholar
• 15. Toptan H, Aslan FG, Karakeçe E, Aydemir Ö, Demiray T, Köroğlu M, et al. Anti-HIV % reaktif saptanan hastaların doğrulama test sonuçları ile birlikte değerlendirilmesi. J Biotechnol and Strategic Health Res 2019; 3(1): 27-32. [CrossRef] google scholar
• 16. Gilead,Türkiye HIV yol haritası- HIV politikalarının değerlendirilmesi ve tavsiyeler. (cited 2022 Nov 29). Available from: https://www. gilead.com.tr/-/media/gilead-turkey/pdfs/gilead-turkey-post-covid-19-hiv-policies.pdf google scholar
• 17. UNAIDS, understanding fast-track, accelerating action to end the AIDS epidemic by 2030 2015. (cited 2022 Nov 29). Available from: https://www.unaids.org/en/resources/documents/2014/JC2686_ WAD2014report google scholar